Showing 1672 results
-
Press release /CHICAGO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the closing of its previously announced underwritten public offering of 4,509,840 shares of its common stock…
-
Story /What drives someone to dedicate their career to reimagining medicine? Three women at Novartis share their deeply personal and unique stories.
-
Press release /CHICAGO, Jan. 16, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS) today announced the pricing of an underwritten public offering of 3,921,600 shares of its common stock at a public offering…
-
Event /During Eurovision week, the Novartis Campus and the Novartis Pavillon will become a cultural hub, offering free public access, engaging experiences, and inspiring…
-
Story /Compounds block a protein involved in many cancers by cementing it shut.
-
Story /Novartis is developing an experimental drug for weight loss.
-
Story /Novartis researchers have discovered a compound that is showing promise against three parasites that cause three neglected diseases.
-
Story /Novartis is taking its investigational gene therapy for a degenerative eye disease into clinical trials.
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating income…